^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    picibanil biosimilar (TARA-002)

    i
    Other names: TARA-002
    Associations

    News

    Trials
    Company:
    Protara Therap
    Drug class:
    TLR4 agonist
    Related drugs:
    Associations

    News

    Trials
    11ms
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (clinicaltrials.gov)
    P1, N=12, Completed, Protara Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    picibanil biosimilar (TARA-002)
    1year
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) (clinicaltrials.gov)
    P1, N=10, Completed, Protara Therapeutics | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024
    Trial completion • Trial completion date
    |
    picibanil biosimilar (TARA-002)
    over1year
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Protara Therapeutics | Recruiting --> Active, not recruiting | N=18 --> 12 | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Oct 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    picibanil biosimilar (TARA-002)
    over1year
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Protara Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    picibanil biosimilar (TARA-002)
    over1year
    ADVANCED-2: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=127, Recruiting, Protara Therapeutics | Phase classification: P1b/2 --> P2 | Trial completion date: Aug 2026 --> Aug 2030 | Trial primary completion date: Aug 2026 --> May 2030
    Phase classification • Trial completion date • Trial primary completion date
    |
    picibanil biosimilar (TARA-002)
    almost2years
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Protara Therapeutics | Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    picibanil biosimilar (TARA-002)
    almost2years
    STARBORN-1: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age (clinicaltrials.gov)
    P2, N=38, Recruiting, Protara Therapeutics | Phase classification: P --> P2
    Phase classification
    |
    picibanil biosimilar (TARA-002)
    almost2years
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (clinicaltrials.gov)
    P1, N=18, Recruiting, Protara Therapeutics | Phase classification: P1a --> P1 | Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Phase classification • Trial completion date • Trial primary completion date
    |
    picibanil biosimilar (TARA-002)
    2years
    STARBORN-1: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age (clinicaltrials.gov)
    P2a/b, N=38, Recruiting, Protara Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    picibanil biosimilar (TARA-002)
    2years
    ADVANCED-2: Dose Expansion, Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1b/2, N=102, Recruiting, Protara Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    picibanil biosimilar (TARA-002)
    over2years
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Protara Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    picibanil biosimilar (TARA-002)
    over2years
    ADVANCED-1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (clinicaltrials.gov)
    P1a, N=18, Recruiting, Protara Therapeutics | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    picibanil biosimilar (TARA-002)